Financial Performance
5Y price score: 105
The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.
A score of 100 indicates that the stock did as well as the S&P 500 Index.
A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.
10Y return: 653.6%
US$ Per
Share
By default your notes are visible only to you.
81.8
52-week range
365.2
Your model inputs
Your fair value & Margin of safety
To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.
Forecast:
Valuation
Free Cash Flow Yield
29.1 %
Dividend Yield TTM
-
Market cap $
$ 41,956
Price / Earnings TTM
(1.3)
Price / Book TTM
1
PEG TTM
0
Earnings growth and return
LTM
5YR
10YR
Total return (price & dividends)
(63) %
74.5 %
653.6 %
Free cash flow per share growth
99.9 %
(591.8) %
(6,586.9) %
Earnings per share growth
(173.8) %
(19,501) %
(1,755.4) %
Business Summary:
Latest Earnings Call Takeaways
2026 Q2 (Jul 30, 2026)
1) Strong Financial Performance and Record Originations - Hercules Capital reported record total investment income of $149.1 million, up 8.5% YoY. - Net investment income reached a record $92.9 million or $0.50 per share, covering the base distribution by 125%. - Originations for Q2 totaled $927 million, contributing to $2.74 billion in record originations for the first half of 2026, a 35.6% YoY increase. - Fundings for Q2 were $647 million, with total fundings for the first half at $1.35 billion, up 8.5% YoY.
2) Portfolio and Credit Quality Management - The investment portfolio is diversified, with approximately 50% in life sciences and 50% in technology. - The weighted average internal credit rating slightly increased to 2.17, with 65.4% of credits rated 1 or 2. - Early loan repayments in Q2 were $572.1 million, exceeding guidance, with 60% attributed to M&A or balance sheet cash. - The number of non-accrual loans increased to two, representing 0.3% of the total investment portfolio at cost.
3) Operational Efficiency and Strategic Growth - The company has expanded its leadership team, with Andrew Olson appointed as CFO and Seth Meyer transitioning to President. - Hercules Adviser, managing nearly $2 billion in committed capital, continues to provide significant cash flows to the public BDC. - The operating cost ratio improved to approximately 2%, reflecting efficient scaling and leveraging existing resources. - Investments in technology and AI governance are aimed at enhancing operational efficiency without compromising proprietary data.
4) Market Outlook and Guidance - For Q3 2026, Hercules expects prepayments to normalize to $200 million-$300 million, with a seasonal slowdown in originations anticipated. - Core yields are projected to be in the range of 11.8%-12%, reflecting the impact of portfolio turnover and new originations. - The company remains optimistic about the investment environment, citing a robust pipeline and ongoing opportunities in both life sciences and technology sectors.
5) Missing Information and Investor Considerations - The transcript does not provide detailed figures on expenses or specific future guidance beyond Q3. - There is a lack of clarity on how competitive pressures from banks may affect future loan terms and origination strategies.
Bottom line: Hercules Capital's strong Q2 performance, characterized by record originations and stable credit quality, positions the company well for continued growth. The proactive management of its diversified portfolio and operational efficiencies, coupled with a robust market outlook, suggest a favorable environment for shareholders moving forward.
Annual Reports, Presentations And IR Contacts
Go to the websiteMicrostrategy Inc. — Financial Overview, Stock Price, Market Cap
Microstrategy Inc. is a company. Founded in 1970. As of August 26, 2026, the company's market capitalization is $41956378640 with a current stock price of $126.83.
